Table 1 Patient baseline characteristics (number = 819).
Characteristic | Number | % |
|---|---|---|
Age at diagnosis | ||
< 50 | 290 | 35.4 |
> 50 | 529 | 64.6 |
T stage | ||
T1 | 613 | 74.8 |
T2 | 195 | 23.8 |
T3 | 11 | 1.4 |
Number of positive nodes | ||
0 | 586 | 71.6 |
1-3 | 219 | 26.7 |
> 4 | 10 | 1.2 |
No nodes sampled | 4 | 0.5 |
Grade | ||
1 | 84 | 10.3 |
2 | 431 | 52.6 |
3 | 300 | 36.6 |
Unknown | 4 | 0.5 |
ER or PR positive | 656 | 80.1 |
HER2 positive | 109 | 13.3 |
LVI present | 137 | 16.7 |
Hormonal therapy received | 553 | 67.5 |
Chemotherapy received | 389 | 47.5 |
Trastuzumab therapy received (if HER2 positive, Number = 108) | 28 | 25.9 |
Margins | ||
Close or positive | 27 | 3.3 |
Negative | 791 | 96.6 |
Unknown | 1 | 0.1 |
Constructed subtype | ||
HR+/HER2+ | 574 | 70 |
HR+HER2+ | 57 | 7 |
HR-/HER2+ | 51 | 6.2 |
HR-/HER2- | 94 | 11.5 |
Unknown | 43 | 5.3 |